Skip to Content
Morningstar

Zymeworks Inc Registered Shs ZYME

Morningstar Rating
Unlock
Stock XNAS Rating as of
$8.43 +0.12 (1.44%)
View Full Chart
As of Cboe BZX Real-Time Price Open
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
ZYME is trading at a 25% discount.
Price
$8.31
Fair Value
$37.88
Uncertainty
Very High
1-Star Price
$35.49
5-Star Price
$7.39
Economic Moat
Rvtwq
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ZYME is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$8.31
Day Range
$8.26–8.54
52-Week Range
$6.02–13.15
Bid/Ask
$8.40 / $8.45
Market Cap
$594.89 Mil
Volume/Avg
43,218 / 590,143

Key Statistics

Price/Earnings (Normalized)
2.54
Price/Sales
7.55
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
277
Website
https://www.zymeworks.com

Comparables

Valuation

View More
Metric
ZYME
MRSN
ZNTL
Price/Earnings (Normalized)
 2.54——
Price/Book Value
 1.2610.341.85
Price/Sales
 7.559.96—
Price/Cash Flow
 ———
Price/Earnings
ZYME
MRSN
ZNTL

Financial Strength

Metric
ZYME
MRSN
ZNTL
Quick Ratio
 7.063.296.96
Current Ratio
 7.413.367.16
Interest Coverage
 —−44.11—
Quick Ratio
ZYME
MRSN
ZNTL

Profitability

Metric
ZYME
MRSN
ZNTL
Return on Assets (Normalized)
 −18.40%−49.57%−33.50%
Return on Equity (Normalized)
 −23.86%−211.52%−41.29%
Return on Invested Capital (Normalized)
 −26.55%−146.81%−37.58%
Return on Assets
ZYME
MRSN
ZNTL
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRWlbzfmqrhGdhk$566.6 Bil
VRTX
Vertex Pharmaceuticals IncQlfqdxqDllkqh$102.4 Bil
REGN
Regeneron Pharmaceuticals IncXwysnwbjYrzgck$98.3 Bil
MRNA
Moderna IncKyqgpdrHclny$42.7 Bil
ARGX
argenx SE ADRQmxlsfwjvCrsj$22.2 Bil
BNTX
BioNTech SE ADRLcktpxkYbj$21.2 Bil
ALNY
Alnylam Pharmaceuticals IncYppznznkfGplhq$18.6 Bil
BMRN
Biomarin Pharmaceutical IncMlgspcmtScctvm$15.6 Bil
RPRX
Royalty Pharma PLC Class ABssmxnsjzQdcqt$12.7 Bil
INCY
Incyte CorpQvwkcjnsZfswm$11.8 Bil

Sponsor Center